백화사설초 및 영지버섯 추출물을 포함하는 바이러스 질환의 예방 및 치료용 조성물
    21.
    发明授权
    백화사설초 및 영지버섯 추출물을 포함하는 바이러스 질환의 예방 및 치료용 조성물 有权
    用于预防和治疗包括白花高原提取物和灵芝提取物的病毒疾病的组合物

    公开(公告)号:KR100504272B1

    公开(公告)日:2005-07-27

    申请号:KR1020040081676

    申请日:2004-10-13

    Abstract: 본 발명은 항바이러스 활성을 나타내는 백화사설초 및 영지버섯 추출물을 포함하는 조성물에 관한 것으로서, 더욱 상세하게는, PMWS 바이러스, PRRS 바이러스, PED 바이러스, TGE 바이러스, 파보 바이러스 및 디스템퍼 바이러스에 대해 우수한 항바이러스 활성을 나타내는 백화사설초 및 영지버섯 추출물을 유효성분으로 함유하는 약학조성물에 관한 것이다.
    본 발명에 따른 조성물은 천연물 유래의 물질로써 독성 및 부작용이 없으며, 다양한 바이러스에 대하여 탁월한 살균효과를 나타내므로, 바이러스 질환의 예방 및 치료에 효과적이고 안전한 동물용 의약품으로 유용하게 이용될 수 있다.

    성장 촉진 또는 성장 호르몬 분비 촉진 효과를 갖는인진쑥 함유 조성물 및 이를 이용하여 코팅된 기능성 코팅곡류
    23.
    发明公开
    성장 촉진 또는 성장 호르몬 분비 촉진 효과를 갖는인진쑥 함유 조성물 및 이를 이용하여 코팅된 기능성 코팅곡류 失效
    含有ARTEMISIA CAPILLARIS THUNB的组合物。 促进生长和生长激素分泌和功能性谷物的效果

    公开(公告)号:KR1020040036272A

    公开(公告)日:2004-04-30

    申请号:KR1020020065230

    申请日:2002-10-24

    Abstract: PURPOSE: A composition containing an Artemisia capillaris thunb. extract as an effective ingredient is provided. It shows excellent effects of promoting growth and growth hormone secretion and can be used a health supplementary food for promoting growth when coated to cereals. CONSTITUTION: A composition for promoting growth and growth hormone secretion comprises 10 to 100% by weight of an Artemisia capillaris thunb. extract, 0 to 90% by weight of herbal plants and 5 to 50% by weight of a starch solution. The herbal plants are one or more components selected from Acanthopanacis Cortex, Acanthopanax Senticosus(Rupr. et Maxim.) Harms, Phlomis umbrosa Turez. Lycii Cortex Radicis, Carthami Flos, Eucommiae Cortex, Poria cocos, Cuscutae Semen, Ginseng Radix, Cervi cornu and calcium. The composition is coated to cereals selected from white rice, unpolished rice, barley, foxtail millet, sorghum or glutinous rice.

    Abstract translation: 目的:含有青蒿的组合物。 提取物作为有效成分。 它显示促进生长和生长激素分泌的优异效果,并且可以用于在涂覆至谷物时促进生长的健康补充食物。 构成:用于促进生长和生长激素分泌的组合物包含10至100重量%的青蒿。 提取物,0至90重量%的草药植物和5至50重量%的淀粉溶液。 草本植物是选自刺五加皮刺,刺五加(Rupr。et Maxim。)Harms,Phlomis umbrosa Turez的一种或多种成分。 枸杞子,Carthami Flos,杜仲皮,茯苓,Cuscutae精液,人参,Cervi cornu和钙。 将组合物涂布到选自白米,未糙米,大麦,粟米,高粱或糯米的谷物中。

    손바닥 선인장 분말의 방출제어형 코팅과립 및 이의제조방법
    24.
    发明公开
    손바닥 선인장 분말의 방출제어형 코팅과립 및 이의제조방법 无效
    释放OPONTIA FICUS-INDICA粉末的控制颗粒及其制备方法

    公开(公告)号:KR1020030090397A

    公开(公告)日:2003-11-28

    申请号:KR1020020028688

    申请日:2002-05-23

    Inventor: 라정찬 이종은

    Abstract: PURPOSE: Provided are release controlled granules of Opuntia ficus-indica powder and a preparing process thereof, thereby effectively blocking the characteristic taste of Opuntia ficus-indica and preventing coloration of a tongue and a tooth. Therefore, it is useful as food material. CONSTITUTION: A preparing process of release controlled granules of Opuntia ficus-indica comprises the steps of: manufacturing granules by mixing Opuntia ficus-indica powder as an active ingredient, a sweetener, a binding agent or diluent; and floating the granule under the condition of low temperature and spraying a coating agent onto the granule.

    Abstract translation: 目的:提供仙人掌榕粉的释放控制颗粒及其制备方法,从而有效地阻断榕果芸苔的特征味,并防止舌和牙的着色。 因此,作为食品材料是有用的。 构成:猕猴桃释放控制颗粒的制备方法包括以下步骤:通过混合作为活性成分的仙茅a粉,甜味剂,粘合剂或稀释剂制造颗粒; 并在低温条件下漂浮颗粒,并将涂层剂喷在颗粒上。

    맛과 향이 차폐된 퀴놀론계 약물의 방출제어과립의 제조방법
    25.
    发明公开
    맛과 향이 차폐된 퀴놀론계 약물의 방출제어과립의 제조방법 无效
    生产基于喹喔啉基的药物和气味掩蔽的控制释放颗粒

    公开(公告)号:KR1020020069377A

    公开(公告)日:2002-09-04

    申请号:KR1020010004563

    申请日:2001-01-31

    CPC classification number: A61K9/5026 A61K9/5015 A61K31/496

    Abstract: PURPOSE: A process of preparing controlled release granules by granulating quinolone-based drug or its salts thereof as a main medicament and then coating using it as a seed is provided. By the absolute masking of the taste and odor characteristics of drug, compliance is remarkably increased when administered orally to an animal. CONSTITUTION: About 1 to 95% by weight of quinolone-based drug or its salts such as enrofloxacin, ciprofloxacin or the like having a specific taste and odor as a main medicament is mixed with 1 to 60% by weight of a sweetening agent to give granules, which are coated with a coating liquid containing a coating base material. But in the case where a powder of quinolone-based drug or its salts has a specific gravity of 0.6g/cm¬3 or more, it is directly coated without manufacturing the granules after mixing with the sweetening agent. In the process, 0.5 to 50% by weight of a plasticizer and 0.5 to 90% by weight of an excipient are additionally added.

    Abstract translation: 目的:提供通过将基于喹诺酮的药物或其盐作为主要药物制粒控制释放颗粒,然后使用其作为种子进行包衣的方法。 通过药物的味道和气味特征的绝对掩蔽,当向动物口服施用时,顺应性显着增加。 构成:将1〜95重量%的喹诺酮类药物或其盐如具有特定味道和气味的恩诺沙星,环丙沙星等作为主要药物与1至60重量%的甜味剂混合,得到 颗粒,其涂覆有包含涂料基材的涂布液。 但是,在喹诺酮类药物或其盐的比重为0.6g / cm 3以上的情况下,在与甜味剂混合后,直接涂布而不制造颗粒。 在该方法中,另外加入0.5〜50重量%的增塑剂和0.5〜90重量%的赋形剂。

    형질전환된 복제개의 생산방법
    26.
    发明公开
    형질전환된 복제개의 생산방법 有权
    生产克隆的转基因癌的方法

    公开(公告)号:KR1020090075637A

    公开(公告)日:2009-07-08

    申请号:KR1020090000331

    申请日:2009-01-05

    CPC classification number: A01K67/0275 A01K2227/10 C07K14/43595 C12N15/873

    Abstract: A method of manufacturing a cloned dog is provided, which uses transfection and targeting technology of the desired gene. A method of manufacturing a cloned dog comprises: a step for producing the donor nucleus cell from the somatic cell line picked from the dog and expressing by introducing the DNA structure containing the target gene; a step for adding the cell cycle synchronization inducing agent and cultivating; a step for producing the nuclear transfer embryo by transplanting the cultivated donor nucleus cell to the denucleated dog recipient; a step for activating; and a step for producing a litter.

    Abstract translation: 提供了制造克隆狗的方法,其使用所需基因的转染和靶向技术。 制造克隆狗的方法包括:从从狗取出的体细胞系中产生供体核细胞并通过引入含有靶基因的DNA结构进行表达的步骤; 添加细胞周期同步诱导剂并培养的步骤; 通过将培养的供体核细胞移植到去核的狗接受者来生产核转移胚的步骤; 激活的一个步骤 以及生产垃圾的步骤。

    간엽줄기세포를 포함하는 간 섬유증 또는 간 경화증의 예방및 치료용 약학 조성물
    28.
    发明公开
    간엽줄기세포를 포함하는 간 섬유증 또는 간 경화증의 예방및 치료용 약학 조성물 无效
    用于预防和治疗包含骨髓干细胞的肝纤维化或肝性循环的药物组合物

    公开(公告)号:KR1020080101140A

    公开(公告)日:2008-11-21

    申请号:KR1020070047472

    申请日:2007-05-16

    CPC classification number: A61K35/51 A61K35/28

    Abstract: A pharmaceutical composition is provided to replace damaged liver cells using mesenchymal stem cell, to recover function of the liver and to prevent and treat a liver fibrosis or a liver sclerosis by reducing collagen fiber deposited in the liver. A composition for preventing and treating a liver fibrosis or a liver sclerosis includes mesenchymal stem cell originated from an umbilical cord blood or a fatty tissue. The umbilical cord blood or the fatty tissue is separated from human. A pharmaceutical composition for preventing and treating the liver fibrosis or the liver sclerosis includes the mesenchymal stem cell originated from the umbilical cord blood or the fatty tissue. The umbilical cord blood or the fatty tissue is separated from human.

    Abstract translation: 提供药物组合物以使用间充质干细胞代替损伤的肝细胞,通过减少沉积在肝脏中的胶原纤维来恢复肝脏的功能并预防和治疗肝纤维化或肝硬化。 用于预防和治疗肝纤维化或肝硬化的组合物包括起源于脐带血或脂肪组织的间充质干细胞。 脐带血或脂肪组织与人分离。 用于预防和治疗肝纤维化或肝硬化的药物组合物包括起源于脐带血或脂肪组织的间充质干细胞。 脐带血或脂肪组织与人分离。

Patent Agency Ranking